TY - JOUR
T1 - Spinal cord and brain corticospinal tract lesions are associated with motor progression in tumefactive multiple sclerosis
AU - Jackson-Tarlton, Caitlin S.
AU - Keegan, B. Mark
AU - Fereidan-Esfahani, Mahboubeh
AU - Barakat, Benan O.
AU - Decker, Paul A.
AU - Lucchinetti, Claudia F.
AU - Eckel-Passow, Jeanette
AU - Tobin, W. Oliver
N1 - Publisher Copyright:
© 2023
PY - 2023/5
Y1 - 2023/5
N2 - Background: Spinal cord lesions have been associated with progressive disease in individuals with typical relapsing remitting MS (RRMS). Objective: In the current study, we aimed to determine if progressive disease is associated with spinal cord lesions in those with tumefactive multiple sclerosis (MS). Methods: Retrospective chart review of individuals presenting to Mayo Clinic with tumefactive MS with spinal cord MRIs available (n=159). Clinical data were extracted by chart review. Brain and spinal cord MRIs were reviewed to characterize the tumefactive demyelinating lesion(s) and assess the burden of spinal cord disease. Results: A total of 69 (43%) had spinal cord lesions. Progressive demyelinating disease was documented in 13 (8%); the majority (11/13) with secondary progressive disease. The method of progression was myelopathic in 8/13 (62%), cognitive in 3/13 (23%), motor from a supratentorial lesion in 2/13 (16%). EDSS at last follow-up was higher in those with progression than those without (median 6.0 (2.0-10.0) vs. 2.5 (0-10.0), p = < 0.001). Progressive demyelinating disease occurred in a minority. Conclusions: Patients with progression typically experienced progressive motor impairment, and this occurred exclusively in individuals with lesions in the corticospinal tracts of the brain and/or the spinal cord.
AB - Background: Spinal cord lesions have been associated with progressive disease in individuals with typical relapsing remitting MS (RRMS). Objective: In the current study, we aimed to determine if progressive disease is associated with spinal cord lesions in those with tumefactive multiple sclerosis (MS). Methods: Retrospective chart review of individuals presenting to Mayo Clinic with tumefactive MS with spinal cord MRIs available (n=159). Clinical data were extracted by chart review. Brain and spinal cord MRIs were reviewed to characterize the tumefactive demyelinating lesion(s) and assess the burden of spinal cord disease. Results: A total of 69 (43%) had spinal cord lesions. Progressive demyelinating disease was documented in 13 (8%); the majority (11/13) with secondary progressive disease. The method of progression was myelopathic in 8/13 (62%), cognitive in 3/13 (23%), motor from a supratentorial lesion in 2/13 (16%). EDSS at last follow-up was higher in those with progression than those without (median 6.0 (2.0-10.0) vs. 2.5 (0-10.0), p = < 0.001). Progressive demyelinating disease occurred in a minority. Conclusions: Patients with progression typically experienced progressive motor impairment, and this occurred exclusively in individuals with lesions in the corticospinal tracts of the brain and/or the spinal cord.
KW - Cortical spinal tract lesions
KW - Encephalopathy
KW - Progressive demyelination
KW - Retrospective chart review
KW - Tumefactive multiple sclerosis (TMS)
UR - http://www.scopus.com/inward/record.url?scp=85150376259&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85150376259&partnerID=8YFLogxK
U2 - 10.1016/j.msard.2023.104614
DO - 10.1016/j.msard.2023.104614
M3 - Article
C2 - 36948092
AN - SCOPUS:85150376259
SN - 2211-0348
VL - 73
JO - Multiple Sclerosis and Related Disorders
JF - Multiple Sclerosis and Related Disorders
M1 - 104614
ER -